ClinicalTrials.gg
CompletedNCT02178592Updated Jan 12, 2021Results posted

Open-label Study of Dolutegravir (DTG) or Efavirenz (EFV) for Human Immunodeficiency Virus (HIV) - Tuberculosis (TB) Co-infection

A Phase 3 interventional study of DTG 50 mg and EFV 600 mg in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 28 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-12.

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

HIV/Tuberculosis (TB) co-infection have profound effects on the host's immune system. TB is the most common cause of death in patients with HIV worldwide. Rifamycins (such as rifampicin [RIF]) are an important component of TB therapy because of their unique activity. The problem is that most protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI) used to treat HIV have significant drug-drug interactions with RIF that can lead to reduced concentrations of these agents with risk of treatment failure or resistance. The non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz (EFV) does not present the same significant drug interactions with RIF. EFV-based HIV treatment was tested in patients concomitantly treated with RIF-containing TB therapy, demonstrating that their co-administration can be used safely and effectively. However, the side effect profile of EFV overlaps with the RIF-containing TB regimens and makes the management of treatment toxicities very complex. Integrase inhibitors (INI), such as dolutegravir (DTG), may offer an important alternative to EFV-based therapy in TB coinfected patients. A Phase I drug-drug interaction study was conducted in healthy, HIV-seronegative subjects, and showed that DTG at 50 mg twice daily given together with RIF was well-tolerated and resulted in DTG concentrations similar to those of DTG 50 mg given once daily alone, which is the recommended dose for INI-naive patients. Therefore, ART regimens using DTG 50 mg twice daily may represent a new treatment option for TB-infected patients who require concurrent treatment for HIV infection. This is a Phase III b, randomized, open-label study describing the efficacy and safety of DTG and EFV-containing ART regimens in HIV/TB co-infected patients. This study is designed to assess the antiviral activity of DTG or efavirenz (EFV) ART-containing regimens through 48 weeks. A total of approximately 115 +/-5% subjects will be randomly assigned in a 3:2 ratio to DTG (approximately 69 subjects) and EFV (approximately 46 subjects), respectively. This study will include a Screening Period, a Randomized Phase (Day 1 to 48 weeks plus a 4-week extension), and a DTG Open-label extension (OLE). During the DTG OLE, subjects will be supplied with DTG until it is locally approved and commercially available, the subject no longer derives clinical benefit, or the subject meets a protocol-defined reason for discontinuation, which ever comes first.

02

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Keywords

  • integrase inhibitor
  • Mycobacterium tuberculosis
  • rifampicin-sensitive
  • dolutegravir
  • antiretroviral therapy-naïve
  • HIV-1 infection
  • efavirenz
  • co-infection
03

In context

Infections

2,096 studies on the registry are indexed under Infections; 364 are open to participants now.

This study's enrollment of 113 is close to the median of 113 across 1,304 interventional studies indexed under Infections.

Browse Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject or the subject's legal representative is willing and able to understand and provide signed and dated written prior to Screening
  • Adult subject (at least 18 years of age) with plasma -1 RNA>=1000 copies/ milliliter (mL) at Screening
  • is >= 50 cells/ cubic millimetre (mm\^3) at Screening
  • HIV-1-infected, ART-naïve; (\<=10 days of prior therapy with any antiretroviral drug following a diagnosis of HIV-1 infection)
  • A female subject may be eligible to enter and participate in the study if she: is of non- defined as either (12 months of spontaneous amenorrhea and >=45 years of age) or physically incapable of becoming pregnant with documented tubal ligation, hysterectomy, or bilateral oophorectomy or, is of childbearing potential, with a negative pregnancy test at both Screening and Day 1, and agrees to use one of the following methods of to avoid pregnancy
  • Complete abstinence from intercourse from 2 weeks prior to administration of IP, throughout the study, and for at least 2 weeks after discontinuation of all study medications
  • Double-barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide)
  • Approved hormonal contraception plus a barrier method while receiving Rifampicin (RIF)-containing TB treatment for subjects randomly assigned to the DTG arm or approved hormonal contraception plus a barrier method for subjects randomly assigned to the EFV arm (regardless of RIF-containing TB treatment)
  • Any intrauterine device with published data showing that the expected failure rate is \<1% per year
  • Male partner sterilization prior to the female subject's entry into the study and this male is the sole partner for that subject
  • Any other method with published data showing that the expected failure rate is \<1% per year
  • Any contraception method must be used consistently, in accordance with the approved product label and for at least 2 weeks after discontinuation of study drug. A childbearing potential female subject who starts the study using complete abstinence as her contraceptive method and decides to become sexually active must use the double barrier method either as a bridge to an approved hormonal contraception (if possible) or as a method of choice to be maintained from that moment onwards
  • All subjects participating in the study should be counseled on safer sexual practices including the use of effective barrier methods
  • New diagnosis of pulmonary, pleural, or Lymph node (LN) TB based on identification of Mycobacterium tuberculosis using culture methods or validated nucleic acid amplification test on sputum or on samples collected by needle aspirate of pleural fluid or an affected LN
  • RIF sensitivity of Mycobacterium tuberculosis either by culture or validated nucleic acid amplification test
  • RIF-containing TB treatment or an alternate RIF-containing TB treatment started up to a maximum of 8 weeks before randomization and no later than the screening date
  • score >=70% before randomization

Exclusion criteria

Exclusion Criteria:

  • Any previous TB treatment (not including treatment for latent disease)
  • Evidence of RIF resistance of Mycobacterium tuberculosis either by culture or validated nucleic acid amplification test
  • Expected requirement for TB treatment >9 months
  • Concomitant disorders or conditions for which isoniazid, RIF, pyrazinamide, or ethambutol are
  • Central nervous system, miliary, or pericardial TB
  • Women who are pregnant or breastfeeding
  • Any evidence of an active Acquired immunodeficiency syndrome (AIDS)-defining disease (Centers for Disease Control and Prevention, Category C). Exceptions include TB, cutaneous Kaposi's sarcoma not requiring systemic therapy, and historic of \<200 cells/mm\^3
  • Subjects with moderate to severe hepatic impairment (Class B or C) as determined by classification unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or persistent jaundice), cirrhosis, or known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
  • Subjects positive for surface antigen (HBsAg) at screening
  • Anticipated need for virus (HCV) therapy during the Randomized Phase of the study
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the study medical monitor for inclusion of the subject
  • Subjects who, in the investigator's judgment, pose a significant suicidality risk. Recent history of suicidal behavior and/or suicidal ideation may be considered as evidence of serious suicide risk
  • Treatment with an -1 immunotherapeutic vaccine within 90 days of Screening
  • Treatment with any of the following agents within 28 days of Screening: radiation therapy, cytotoxic chemotherapeutic agents, any immunomodulators that alter immune response
  • Treatment with any agent, other than licensed ART as allowed above with documented activity against HIV-1 in vitro/vivo within 28 days of first dose of IP
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of IP
  • Any evidence of primary viral resistance to Nucleoside reverse transcriptase inhibitor (NRTIs), Non-nucleoside reverse transcriptase inhibitor (NNRTIs), or Protease inhibitor (PIs) based on the presence of any major resistance-associated mutation (according to the International AIDS Society Update of the Drug Resistant Mutations in HIV-1 ) in the Screening result or, if known, any historical resistance test result. Note: Retests of Screening genotypes are not allowed
  • Any verified Grade 4 laboratory abnormality
  • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the subject's participation in the study of an compound
  • >=2 ×
  • \<=7.4 grams per deciliter;
  • count \<50000/mm\^3
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Dolutegravir

    Twice-daily DTG 50 mg plus dual NRTI during RIF-containing TB treatment (isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions or acceptable alternative RIF-containing regimens) and for 2 weeks following discontinuation of TB treatment, then once-daily DTG 50 mg with the same NRTI through Week 52

    Drug: DTG 50 mg

  • Active comparator
    Efavirenz

    Once-daily EFV 600 mg plus dual NRTI through Week 52 along with TB treatment including isoniazid, RIF, pyrazinamide and ethambutol standard doses by the NTP under program conditions.

    Drug: EFV 600 mg

Interventions

  • DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food

  • DrugEFV 600 mg

    EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United States (US) Food and Drug Administration (FDA) Snapshot Algorithm

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter was assessed at Week 48 using the snapshot algorithm in the DTG arm. Response was assessed using a modified FDA Snapshot algorithm in which participants were not penalized for any single protocol allowed background therapy substitution even if occurs after the first trial visit. In this approach participants with HIV-1 RNA \>=50 copies/milliliter are considered as non-responders. Participants without HIV-1 RNA data at Week 48 (due to missing data or discontinuation of investigational product \[IP\] prior to visit window) are also considered as non-responders, as well as participants with anti-retroviral (ART) substitutions were not permitted. Study drug (i.e. DTG or EFV) was not allowed to be substituted.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 48 in EFV Arm Using the Modified Snapshot Algorithm

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter were assessed at Week 48 using the snapshot algorithm in the EFV arm. Response was assessed using a modified FDA Snapshot algorithm in which participants were not penalized for any single protocol allowed background therapy substitution even if occurs after the first trial visit. In this approach participants with HIV-1 RNA \>=50 copies/milliliter are considered as non-responders. Participants without HIV-1 RNA data at Week 48 (due to missing data or discontinuation of IP prior to visit window) are also considered as non-responders, as well as participants with ART substitutions were not permitted. Study drug (i.e. DTG or EFV) was not allowed to be substituted.

    Time frame: Week 48

  2. Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 24 in Both EFV and DTG Arms Using the Modified Snapshot Algorithm

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter were assessed at Week 24 using the snapshot algorithm in the DTG and EFV arm. Response was assessed according to the Modified Snapshot algorithm. In this approach participants with HIV-1 RNA \>=50 copies/milliliter were considered non-responders. Participants without HIV-1 RNA data at Week 24 (due to missing data or discontinuation of IP prior to visit window) were also considered as non-responders, as well as participants with ART substitutions were not permitted. Substitution of a background NRTI agent was permissible one time if it was due to reasons of drug toxicity.

    Time frame: Week 24

  3. Percentage of Participants Without Confirmed Virologic Withdrawal and Without Discontinuation Due to Treatment-related Reasons at Week 24 and Week 48

    Percentage of participants not meeting confirmed virologic withdrawal criteria nor discontinued due to treatment related reasons at the time of analysis at Week 24 (through Day 210) and Week 48 (through Day 350) has been presented by treatment group. The time to meeting confirmed virologic withdrawal criteria or discontinuation due to treatment related reasons (i.e., discontinuation due to drug-related adverse event \[AE\], or due to protocol defined safety stopping criteria, or due to lack of efficacy) were calculated. Participants who met confirmed virologic withdrawal criteria or discontinuation due to treatment related reasons were considered as Failure. Participants who had not met confirmed virologic withdrawal criteria (per protocol) and were ongoing in the study, or who had discontinued for reasons other than those related to treatment, were censored. This would be the Treatment-Related Discontinuation = Failure (TRDF) data.

    Time frame: Week 24 and Week 48

  4. Change From Baseline in Cluster of Differentiation 4 (CD4+) Counts at Week 24 and Week 48

    Blood samples were collected for assessment of lymphocyte subsets (CD4+ lymphocyte count) by flow cytometry at Baseline and Weeks 24, 48. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Change from Baseline was calculated subtracting the value at the specified time point from the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  5. Number of Participants With Serious Adverse Event (SAE) and Common (>=5%) Non-serious AE (Non-SAE) - Randomized Phase

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, all events of possible drug-induced liver injury with hyperbilirubinemia or any other situation according to medical or scientific judgment. Data for number of participants with SAE and common (\>=5%) non-SAE over 52 weeks has been summarized.

    Time frame: Up to Week 52

  6. Number of Participants With SAE and Common (>=5%) Non-SAE - OLE Phase

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, all events of possible drug-induced liver injury with hyperbilirubinemia or any other situation according to medical or scientific judgment. Data for number of participants with SAE and common (\>=5%) non-SAE from Week 52 to Week 252 has been summarized.

    Time frame: Week 52 to Week 252

  7. Number of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities - Randomized Phase

    Blood samples for assessment of clinical chemistry parameters were collected at indicated time points. Clinical chemistry assessments included alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, carbon dioxide, cholesterol, creatine kinase, creatinine, glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, potassium, and sodium. Data for number of participants who experienced maximum post-Baseline emergent chemistry toxicities were summarized. Maximum post-Baseline emergent chemistry toxicities were graded using Division of Acquired Immune Deficiency Syndrome (DAIDS) toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.

    Time frame: Up to Week 52

  8. Number of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities- Randomized Phase + OLE Phase

    Blood samples for assessment of clinical chemistry parameters were collected at indicated time points. Clinical chemistry assessments included ALT, albumin, alkaline phosphatase, AST, bilirubin, carbon dioxide, cholesterol, creatine kinase, creatinine, glucose, LDL cholesterol calculation, lipase, phosphate, potassium, and sodium. Data for number of participants with maximum post-Baseline emergent chemistry toxicities were summarized. Maximum post-Baseline emergent chemistry toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating) . Higher grade indicates more severity.

    Time frame: Up to Week 252

  9. Number of Participants With Maximum Post-Baseline-emergent Hematology Toxicities- Randomized Phase

    Blood samples for assessment of hematology parameters were collected at indicated time points. Hematology assessments included hemoglobin, leukocytes, neutrophils and platelets. Data for number of participants who experienced maximum post-Baseline emergent hematology toxicities were summarized. Maximum post-Baseline emergent hematology toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.

    Time frame: Up to Week 52

  10. Number of Participants With Maximum Post-Baseline-emergent Hematology Toxicities - Randomized Phase + OLE Phase

    Blood samples for assessment of hematology parameters were collected at indicated time points. Hematology assessments included hemoglobin, leukocytes, neutrophils and platelets. Data for number of participants who experienced maximum post-Baseline emergent hematology toxicities were summarized. Maximum post-Baseline emergent hematology toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.

    Time frame: Up to Week 252

  11. Percent Change From Baseline in the Fasting Lipid Profile at Week 24 and Week 48

    Samples for lipid measurements were obtained in a fasted state at Baseline, Week 24 and Week 48. The parameters assessed during the lipid profile were total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Percent change from Baseline for a parameter was calculated as the observed value minus the Baseline value divided by Baseline value multiplied by 100. Data for fasting lipid parameters has been summarized.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  12. Change From Baseline in the Fasting Lipid Profile for Total Cholesterol/HDL Ratio at Week 24 and Week 48

    Samples for lipid measurements were obtained in a fasted state at Baseline, Week 24 and Week 48. The parameter assessed during the lipid profile was total cholesterol/HDL ratio. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Change from baseline for a parameter was calculated as the observed value minus the Baseline value.

    Time frame: Baseline (Day 1), Week 24 and Week 48

  13. Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - Randomized Phase

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Data for percentage of participants who permanently discontinued study treatment due to any AE over 52 weeks has been summarized.

    Time frame: Up to Week 52

  14. Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - OLE Phase

    An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Data for percentage of participants who permanently discontinued study treatment due to any AE from Week 52 to Week 252 has been summarized.

    Time frame: Week 52 to Week 252

  15. Number of Participants With Tuberculosis (TB) Associated (Assoc.) Immune Reconstitution Inflammatory Syndrome (IRIS)

    Participants were monitored for signs and symptoms of TB-assoc. IRIS. Participants with IRIS symptoms in any AE or HIV assoc. conditions were classified by Endpoint Adjudication Committee in following four categories: met criteria for TB-assoc. IRIS, possibly met criteria for TB-assoc. IRIS, suspected TB-assoc. IRIS but not possible to adjudicate and No TB associated IRIS. They were further graded from Grades 1 to 4 using DAIDS. Higher grade indicates more severity. The preliminary requirements to meet TB-assoc. IRIS criteria were diagnosis of TB and initial response to TB treatment (stabilized or improved condition of participant in presence of TB treatment before starting ART). The clinical criteria was onset of IRIS signs and symptoms related to TB should occur within first 3 months of starting, restarting or changing ART regimen for treatment failure. Number of participants who sent to the adjudication committee and analyzed were presented.

    Time frame: Up to Week 12

  16. Number of Participants With Treatment-emergent Genotypic Resistance

    Whole venous blood samples were obtained from each participant until Week 52 for potential viral genotypic and phenotypic analyses. Genotypic and phenotypic testing was conducted for participants meeting confirmed virologic withdrawal criteria, i.e., confirmed HIV-1 RNA \>=400 copies/milliliter from Week 24 onwards. Genotypic and phenotypic analyses was carried out by Monogram Biosciences using, but not limited to, their Standard Phenosense and GenoSure testing methods for protease (PRO), reverse transcriptase (RT), and integrase assays. Data for number of participants with treatment-emergent genotypic resistance mutations have been presented for the RT region on codons G190G, K101K, K103K, K65K, V106V and Y181Y.

    Time frame: Up to Week 52

  17. Number of Participants With Treatment-emergent Phenotypic Resistance

    Phenotypic susceptibility to all licensed antiretroviral drugs, including DTG and EFV were determined using PhenoSense HIV assays from Monogram Inc. Clinical cutoffs or biological cutoffs by PhenoSense were used to define the phenotypic susceptibility of background treatment and were interpreted as fold change \> clinical lower cut-off or biologic cut-off as resistance, fold change \<=clinical lower cut-off or biologic cut-off as sensitive, and fold change \> clinical higher cut-off as resistance, fold change \<=clinical higher cut-off and \> clinical lower cut-off as partially sensitive, and fold change \<=clinical lower cut-off as sensitive. Data has been presented for participants with treatment-emergent phenotypic resistance.

    Time frame: Up to Week 52

07

Results

Posted Feb 21, 2019

Participant flow

This study was conducted in 7 countries across 25 centers; Argentina (2), Brazil (4), Mexico (3), Peru (4), Russia (2), South Africa (8) and Thailand (2). Participants were randomized to receive either Dolutegravir (DTG) or Efavirenz (EFV) containing regimens.

Randomized Phase (Up to Week 52)
Participant flow — Randomized Phase (Up to Week 52)
MilestoneDTG 50 mgEFV 600 mg
Started6944
Completed5035
Not completed199
Withdrew: Adverse event02
Withdrew: Lack of efficacy11
Withdrew: Protocol violation32
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up113
Withdrew: Physician decision10
OLE Phase (Week 52 to Week 252)
Participant flow — OLE Phase (Week 52 to Week 252)
MilestoneDTG 50 mgEFV 600 mg
Started4719
Completed3516
Not completed123
Withdrew: Adverse event10
Withdrew: Lack of efficacy01
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject41
Withdrew: Reached protocol defined stopping criteria20
Withdrew: Lost to follow-up31

Outcome measures

PrimaryPercentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United States (US) Food and Drug Administration (FDA) Snapshot Algorithm

Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter was assessed at Week 48 using the snapshot algorithm in the DTG arm. Response was assessed using a modified FDA Snapshot algorithm in which participants were not penalized for any single protocol allowed background therapy substitution even if occurs after the first trial visit. In this approach participants with HIV-1 RNA \>=50 copies/milliliter are considered as non-responders. Participants without HIV-1 RNA data at Week 48 (due to missing data or discontinuation of investigational product \[IP\] prior to visit window) are also considered as non-responders, as well as participants with anti-retroviral (ART) substitutions were not permitted. Study drug (i.e. DTG or EFV) was not allowed to be substituted.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United States (US) Food and Drug Administration (FDA) Snapshot Algorithm
Percentage of participantsDTG 50 mg
Percentage of Participants With Plasma Human Immunodeficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) < 50 Copies/Milliliter at Week 48 in DTG Arm Using the Modified United States (US) Food and Drug Administration (FDA) Snapshot Algorithm75 (65 to 86)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 48 in EFV Arm Using the Modified Snapshot Algorithm

Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter were assessed at Week 48 using the snapshot algorithm in the EFV arm. Response was assessed using a modified FDA Snapshot algorithm in which participants were not penalized for any single protocol allowed background therapy substitution even if occurs after the first trial visit. In this approach participants with HIV-1 RNA \>=50 copies/milliliter are considered as non-responders. Participants without HIV-1 RNA data at Week 48 (due to missing data or discontinuation of IP prior to visit window) are also considered as non-responders, as well as participants with ART substitutions were not permitted. Study drug (i.e. DTG or EFV) was not allowed to be substituted.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 48 in EFV Arm Using the Modified Snapshot Algorithm
Percentage of participantsEFV 600 mg
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 48 in EFV Arm Using the Modified Snapshot Algorithm82 (70 to 93)
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 24 in Both EFV and DTG Arms Using the Modified Snapshot Algorithm

Plasma samples were collected for quantitative analysis of HIV-1 RNA. The percentage of participants with plasma HIV-1 RNA \<50 copies/milliliter were assessed at Week 24 using the snapshot algorithm in the DTG and EFV arm. Response was assessed according to the Modified Snapshot algorithm. In this approach participants with HIV-1 RNA \>=50 copies/milliliter were considered non-responders. Participants without HIV-1 RNA data at Week 24 (due to missing data or discontinuation of IP prior to visit window) were also considered as non-responders, as well as participants with ART substitutions were not permitted. Substitution of a background NRTI agent was permissible one time if it was due to reasons of drug toxicity.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 24 in Both EFV and DTG Arms Using the Modified Snapshot Algorithm
Percentage of participantsDTG 50 mgEFV 600 mg
Percentage of Participants With Plasma HIV-1 RNA <50 Copies/Milliliter at Week 24 in Both EFV and DTG Arms Using the Modified Snapshot Algorithm81 (72 to 90)89 (79 to 98)
SecondaryPercentage of Participants Without Confirmed Virologic Withdrawal and Without Discontinuation Due to Treatment-related Reasons at Week 24 and Week 48

Percentage of participants not meeting confirmed virologic withdrawal criteria nor discontinued due to treatment related reasons at the time of analysis at Week 24 (through Day 210) and Week 48 (through Day 350) has been presented by treatment group. The time to meeting confirmed virologic withdrawal criteria or discontinuation due to treatment related reasons (i.e., discontinuation due to drug-related adverse event \[AE\], or due to protocol defined safety stopping criteria, or due to lack of efficacy) were calculated. Participants who met confirmed virologic withdrawal criteria or discontinuation due to treatment related reasons were considered as Failure. Participants who had not met confirmed virologic withdrawal criteria (per protocol) and were ongoing in the study, or who had discontinued for reasons other than those related to treatment, were censored. This would be the Treatment-Related Discontinuation = Failure (TRDF) data.

Time frame:
Week 24 and Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Without Confirmed Virologic Withdrawal and Without Discontinuation Due to Treatment-related Reasons at Week 24 and Week 48
Percentage of participantsDTG 50 mgEFV 600 mg
Week 2498.4 (89.1 to 99.8)95.2 (82.1 to 98.8)
Week 4896.6 (87.0 to 99.1)92.7 (79.1 to 97.6)
SecondaryChange From Baseline in Cluster of Differentiation 4 (CD4+) Counts at Week 24 and Week 48

Blood samples were collected for assessment of lymphocyte subsets (CD4+ lymphocyte count) by flow cytometry at Baseline and Weeks 24, 48. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Change from Baseline was calculated subtracting the value at the specified time point from the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · Cells per millimeter^3
Change From Baseline in Cluster of Differentiation 4 (CD4+) Counts at Week 24 and Week 48
Cells per millimeter^3DTG 50 mgEFV 600 mg
Week 24, n=61,41153.2 ± 125.09127.1 ± 158.14
Week 48, n=49, 33199.0 ± 146.22194.5 ± 137.81
SecondaryNumber of Participants With Serious Adverse Event (SAE) and Common (>=5%) Non-serious AE (Non-SAE) - Randomized Phase

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, all events of possible drug-induced liver injury with hyperbilirubinemia or any other situation according to medical or scientific judgment. Data for number of participants with SAE and common (\>=5%) non-SAE over 52 weeks has been summarized.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Event (SAE) and Common (>=5%) Non-serious AE (Non-SAE) - Randomized Phase
ParticipantsDTG 50 mgEFV 600 mg
Common Non-SAE3833
SAE55
SecondaryNumber of Participants With SAE and Common (>=5%) Non-SAE - OLE Phase

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward medical occurrence that, at any dose that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, all events of possible drug-induced liver injury with hyperbilirubinemia or any other situation according to medical or scientific judgment. Data for number of participants with SAE and common (\>=5%) non-SAE from Week 52 to Week 252 has been summarized.

Time frame:
Week 52 to Week 252
Reported as:
Count of participants · Participants
Number of Participants With SAE and Common (>=5%) Non-SAE - OLE Phase
ParticipantsDTG 50 mgEFV 600 mg
Common Non-SAE3616
SAE52
SecondaryNumber of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities - Randomized Phase

Blood samples for assessment of clinical chemistry parameters were collected at indicated time points. Clinical chemistry assessments included alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), bilirubin, carbon dioxide, cholesterol, creatine kinase, creatinine, glucose, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphate, potassium, and sodium. Data for number of participants who experienced maximum post-Baseline emergent chemistry toxicities were summarized. Maximum post-Baseline emergent chemistry toxicities were graded using Division of Acquired Immune Deficiency Syndrome (DAIDS) toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities - Randomized Phase
ParticipantsDTG 50 mgEFV 600 mg
ALT, Grade 1109
ALT, Grade 211
ALT, Grade 311
ALT, Grade 400
Albumin, Grade 122
Albumin, Grade 281
Albumin, Grade 300
Albumin, Grade 400
Alkaline phosphatase, Grade 1711
Alkaline phosphatase, Grade 201
Alkaline phosphatase, Grade 300
Alkaline phosphatase, Grade 400
AST, Grade 1118
AST, Grade 243
AST, Grade 300
AST, Grade 411
Bilirubin, Grade 133
Bilirubin, Grade 210
Bilirubin, Grade 300
Bilirubin, Grade 400
Carbon dioxide, Grade 1148
Carbon dioxide, Grade 244
Carbon dioxide, Grade 310
Carbon dioxide, Grade 400
Cholesterol, Grade 156
Cholesterol, Grade 212
Cholesterol, Grade 300
Cholesterol, Grade 400
Creatine kinase, Grade 134
Creatine kinase, Grade 200
Creatine kinase, Grade 300
Creatine kinase, Grade 411
Creatinine, Grade 120
Creatinine, Grade 200
Creatinine, Grade 301
Creatinine, Grade 400
Glucose, Grade 11110
Glucose, Grade 235
Glucose, Grade 300
Glucose, Grade 400
LDL cholesterol calculation, Grade 103
LDL cholesterol calculation, Grade 210
LDL cholesterol calculation, Grade 300
LDL cholesterol calculation, Grade 400
Lipase, Grade 122
Lipase, Grade 202
Lipase, Grade 300
Lipase, Grade 401
Phosphate, Grade 153
Phosphate, Grade 235
Phosphate, Grade 310
Phosphate, Grade 400
Potassium, Grade 153
Potassium, Grade 202
Potassium, Grade 300
Potassium, Grade 411
Sodium, Grade 1179
Sodium, Grade 223
Sodium, Grade 310
Sodium, Grade 400
SecondaryNumber of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities- Randomized Phase + OLE Phase

Blood samples for assessment of clinical chemistry parameters were collected at indicated time points. Clinical chemistry assessments included ALT, albumin, alkaline phosphatase, AST, bilirubin, carbon dioxide, cholesterol, creatine kinase, creatinine, glucose, LDL cholesterol calculation, lipase, phosphate, potassium, and sodium. Data for number of participants with maximum post-Baseline emergent chemistry toxicities were summarized. Maximum post-Baseline emergent chemistry toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating) . Higher grade indicates more severity.

Time frame:
Up to Week 252
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline-emergent Chemistry Toxicities- Randomized Phase + OLE Phase
ParticipantsDTG 50 mgEFV 600 mg
ALT, Grade 11210
ALT, Grade 232
ALT, Grade 311
ALT, Grade 400
Albumin, Grade 122
Albumin, Grade 281
Albumin, Grade 300
Albumin, Grade 400
Alkaline phosphatase, Grade 1812
Alkaline phosphatase, Grade 201
Alkaline phosphatase, Grade 300
Alkaline phosphatase, Grade 400
AST, Grade 1148
AST, Grade 263
AST, Grade 311
AST, Grade 411
Bilirubin, Grade 173
Bilirubin, Grade 210
Bilirubin, Grade 300
Bilirubin, Grade 400
Carbon dioxide, Grade 11610
Carbon dioxide, Grade 254
Carbon dioxide, Grade 310
Carbon dioxide, Grade 400
Cholesterol, Grade 156
Cholesterol, Grade 212
Cholesterol, Grade 300
Cholesterol, Grade 400
Creatine kinase, Grade 174
Creatine kinase, Grade 211
Creatine kinase, Grade 300
Creatine kinase, Grade 421
Creatinine, Grade 120
Creatinine, Grade 210
Creatinine, Grade 301
Creatinine, Grade 400
Glucose, Grade 11212
Glucose, Grade 275
Glucose, Grade 300
Glucose, Grade 400
LDL cholesterol calculation, Grade 103
LDL cholesterol calculation, Grade 210
LDL cholesterol calculation, Grade 300
LDL cholesterol calculation, Grade 400
Lipase, Grade 132
Lipase, Grade 203
Lipase, Grade 300
Lipase, Grade 401
Phosphate, Grade 155
Phosphate, Grade 2107
Phosphate, Grade 311
Phosphate, Grade 400
Potassium, Grade 183
Potassium, Grade 202
Potassium, Grade 300
Potassium, Grade 411
Sodium, Grade 1229
Sodium, Grade 233
Sodium, Grade 310
Sodium, Grade 400
SecondaryNumber of Participants With Maximum Post-Baseline-emergent Hematology Toxicities- Randomized Phase

Blood samples for assessment of hematology parameters were collected at indicated time points. Hematology assessments included hemoglobin, leukocytes, neutrophils and platelets. Data for number of participants who experienced maximum post-Baseline emergent hematology toxicities were summarized. Maximum post-Baseline emergent hematology toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline-emergent Hematology Toxicities- Randomized Phase
ParticipantsDTG 50 mgEFV 600 mg
Hemoglobin, Grade 121
Hemoglobin, Grade 200
Hemoglobin, Grade 300
Hemoglobin, Grade 400
Leukocytes, Grade 141
Leukocytes, Grade 200
Leukocytes, Grade 301
Leukocytes, Grade 401
Neutrophils, Grade 163
Neutrophils, Grade 221
Neutrophils, Grade 310
Neutrophils, Grade 412
Platelets, Grade 121
Platelets, Grade 200
Platelets, Grade 310
Platelets, Grade 400
SecondaryNumber of Participants With Maximum Post-Baseline-emergent Hematology Toxicities - Randomized Phase + OLE Phase

Blood samples for assessment of hematology parameters were collected at indicated time points. Hematology assessments included hemoglobin, leukocytes, neutrophils and platelets. Data for number of participants who experienced maximum post-Baseline emergent hematology toxicities were summarized. Maximum post-Baseline emergent hematology toxicities were graded using DAIDS toxicity grading for HIV-infected participants as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe) and Grade 4 (potentially life-threating). Higher grade indicates more severity.

Time frame:
Up to Week 252
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline-emergent Hematology Toxicities - Randomized Phase + OLE Phase
ParticipantsDTG 50 mgEFV 600 mg
Hemoglobin, Grade 121
Hemoglobin, Grade 210
Hemoglobin, Grade 300
Hemoglobin, Grade 400
Leukocytes, Grade 153
Leukocytes, Grade 211
Leukocytes, Grade 301
Leukocytes, Grade 401
Neutrophils, Grade 142
Neutrophils, Grade 253
Neutrophils, Grade 320
Neutrophils, Grade 423
Platelets, Grade 102
Platelets, Grade 210
Platelets, Grade 320
Platelets, Grade 400
SecondaryPercent Change From Baseline in the Fasting Lipid Profile at Week 24 and Week 48

Samples for lipid measurements were obtained in a fasted state at Baseline, Week 24 and Week 48. The parameters assessed during the lipid profile were total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol, triglycerides. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Percent change from Baseline for a parameter was calculated as the observed value minus the Baseline value divided by Baseline value multiplied by 100. Data for fasting lipid parameters has been summarized.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · Percent change
Percent Change From Baseline in the Fasting Lipid Profile at Week 24 and Week 48
Percent changeDTG 50 mgEFV 600 mg
Cholesterol, Week 24, n=58, 406.314 ± 20.703616.443 ± 22.0445
Cholesterol, Week 48, n=47, 34-0.375 ± 21.489017.371 ± 20.6312
HDL Cholesterol, Week 24, n=58, 4039.002 ± 53.506039.174 ± 49.1087
HDL Cholesterol, Week 48, n=47, 3424.987 ± 48.247145.423 ± 52.9949
LDL Cholesterol, Week 24, n=58, 404.315 ± 31.709513.487 ± 36.2511
LDL Cholesterol, Week 48, n=47, 34-2.957 ± 31.99109.132 ± 41.1942
Triglycerides, Week 24, n=58, 40-22.744 ± 33.414816.934 ± 118.7319
Triglycerides, Week 48, n=47, 34-18.402 ± 39.022713.175 ± 57.0389
SecondaryChange From Baseline in the Fasting Lipid Profile for Total Cholesterol/HDL Ratio at Week 24 and Week 48

Samples for lipid measurements were obtained in a fasted state at Baseline, Week 24 and Week 48. The parameter assessed during the lipid profile was total cholesterol/HDL ratio. Baseline was defined as the last pre-treatment value observed (typically from Day 1 visit). Change from baseline for a parameter was calculated as the observed value minus the Baseline value.

Time frame:
Baseline (Day 1), Week 24 and Week 48
Reported as:
Mean · Ratio of total cholesterol to HDL
Change From Baseline in the Fasting Lipid Profile for Total Cholesterol/HDL Ratio at Week 24 and Week 48
Ratio of total cholesterol to HDLDTG 50 mgEFV 600 mg
Total cholesterol/HDL ratio, Week 24, n=58, 40-16.292 ± 22.798236.562 ± 315.0478
Total cholesterol/HDL ratio, Week 48, n=47, 34-11.949 ± 27.5044-11.051 ± 28.3183
SecondaryPercentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - Randomized Phase

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Data for percentage of participants who permanently discontinued study treatment due to any AE over 52 weeks has been summarized.

Time frame:
Up to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - Randomized Phase
Percentage of participantsDTG 50 mgEFV 600 mg
Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - Randomized Phase05
SecondaryPercentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - OLE Phase

An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Data for percentage of participants who permanently discontinued study treatment due to any AE from Week 52 to Week 252 has been summarized.

Time frame:
Week 52 to Week 252
Reported as:
Number · Percentage of participants
Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - OLE Phase
Percentage of participantsDTG 50 mgEFV 600 mg
Percentage of Participants Who Permanently Discontinued Study Treatment Due to AEs - OLE Phase40
SecondaryNumber of Participants With Tuberculosis (TB) Associated (Assoc.) Immune Reconstitution Inflammatory Syndrome (IRIS)

Participants were monitored for signs and symptoms of TB-assoc. IRIS. Participants with IRIS symptoms in any AE or HIV assoc. conditions were classified by Endpoint Adjudication Committee in following four categories: met criteria for TB-assoc. IRIS, possibly met criteria for TB-assoc. IRIS, suspected TB-assoc. IRIS but not possible to adjudicate and No TB associated IRIS. They were further graded from Grades 1 to 4 using DAIDS. Higher grade indicates more severity. The preliminary requirements to meet TB-assoc. IRIS criteria were diagnosis of TB and initial response to TB treatment (stabilized or improved condition of participant in presence of TB treatment before starting ART). The clinical criteria was onset of IRIS signs and symptoms related to TB should occur within first 3 months of starting, restarting or changing ART regimen for treatment failure. Number of participants who sent to the adjudication committee and analyzed were presented.

Time frame:
Up to Week 12
Reported as:
Count of participants · Participants
Number of Participants With Tuberculosis (TB) Associated (Assoc.) Immune Reconstitution Inflammatory Syndrome (IRIS)
ParticipantsDTG 50 mgEFV 600 mg
Met criteria for TB-assoc. IRIS, Grade 110
Met criteria for TB-assoc. IRIS, Grade 223
Met criteria for TB-assoc. IRIS, Grade 310
Met criteria for TB-assoc. IRIS, Grade 401
Possibly met criteria for TB-assoc. IRIS, Grade 100
Possibly met criteria for TB-assoc. IRIS, Grade 200
Possibly met criteria for TB-assoc. IRIS, Grade 300
Possibly met criteria for TB-assoc. IRIS, Grade 400
Suspected TB-assoc. IRIS unable to adjudicate, Grade 100
Suspected TB-assoc. IRIS unable to adjudicate, Grade 200
Suspected TB-assoc. IRIS unable to adjudicate, Grade 300
Suspected TB-assoc. IRIS unable to adjudicate, Grade 400
No TB associated IRIS58
SecondaryNumber of Participants With Treatment-emergent Genotypic Resistance

Whole venous blood samples were obtained from each participant until Week 52 for potential viral genotypic and phenotypic analyses. Genotypic and phenotypic testing was conducted for participants meeting confirmed virologic withdrawal criteria, i.e., confirmed HIV-1 RNA \>=400 copies/milliliter from Week 24 onwards. Genotypic and phenotypic analyses was carried out by Monogram Biosciences using, but not limited to, their Standard Phenosense and GenoSure testing methods for protease (PRO), reverse transcriptase (RT), and integrase assays. Data for number of participants with treatment-emergent genotypic resistance mutations have been presented for the RT region on codons G190G, K101K, K103K, K65K, V106V and Y181Y.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Genotypic Resistance
ParticipantsDTG 50 mgEFV 600 mg
G190G (wild type)20
G190G/A01
K101K (wild type)20
K101K/E01
K103K (wild type)20
K103K/N01
K65K (wild type)20
K65R01
V106V (wild type)20
V106M01
Y181Y (wild type)20
Y181Y/C01
SecondaryNumber of Participants With Treatment-emergent Phenotypic Resistance

Phenotypic susceptibility to all licensed antiretroviral drugs, including DTG and EFV were determined using PhenoSense HIV assays from Monogram Inc. Clinical cutoffs or biological cutoffs by PhenoSense were used to define the phenotypic susceptibility of background treatment and were interpreted as fold change \> clinical lower cut-off or biologic cut-off as resistance, fold change \<=clinical lower cut-off or biologic cut-off as sensitive, and fold change \> clinical higher cut-off as resistance, fold change \<=clinical higher cut-off and \> clinical lower cut-off as partially sensitive, and fold change \<=clinical lower cut-off as sensitive. Data has been presented for participants with treatment-emergent phenotypic resistance.

Time frame:
Up to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Phenotypic Resistance
ParticipantsDTG 50 mgEFV 600 mg
Dolutegravir, Sensitive, n=1,111
Dolutegravir, Partially sensitive, n=1,100
Dolutegravir, Resistance, n=1,100
Elvitegravir, Sensitive, n=1,111
Elvitegravir, Resistance, n=1,100
Raltegravir, Sensitive, n=1,111
Raltegravir, Resistance, n=1,100
Delavirdine, Sensitive, n=2,121
Delavirdine, Resistance, n=2,100
Efavirenz, Sensitive, n=2,120
Efavirenz, Resistance, n=2,101
Etravirine, Sensitive, n=2,121
Etravirine, Partially sensitive, n=2,100
Etravirine, Resistance, n=2,100
Nevirapine, Sensitive, n=2,120
Nevirapine, Resistance, n=2,101
Rilpivirine, Sensitive, n=2,121
Rilpivirine, Resistance, n=2,100
Abacavir, Sensitive, n=2,121
Abacavir, Partially sensitive, n=2,100
Abacavir, Resistance, n=2,100
Didanosine, Sensitive, n=2,120
Didanosine, Partially sensitive, n=2,100
Didanosine, Resistance, n=2,101
Emtricitabine, Sensitive, n=2,120
Emtricitabine, Resistance, n=2,101
Lamivudine, Sensitive, n=2,120
Lamivudine, Resistance, n=2,101
Stavudine, Sensitive, n=2,121
Stavudine, Resistance, n=2,100
Tenofovir, Sensitive, n=2,120
Tenofovir, Partially sensitive, n=2,101
Tenofovir, Resistance, n=2,100
Zidovudine, Sensitive, n=2,121
Zidovudine, Resistance, n=2,100
Atazanavir, Sensitive, n=2,121
Atazanavir, Resistance, n=2,100
Darunavir, Sensitive, n=2,121
Darunavir, Partially sensitive, n=2,100
Darunavir, Resistance, n=2,100
Fosamprenavir, Sensitive, n=2,121
Fosamprenavir, Partially sensitive, n=2,100
Fosamprenavir, Resistance, n=2,100
Indinavir,Sensitive, n=2,121
Indinavir, Resistance, n=2,100
Lopinavir, Sensitive, n=2,121
Lopinavir, Partially sensitive, n=2,100
Lopinavir, Resistance, n=2,100
Nelfinavir, Sensitive, n=2,121
Nelfinavir, Resistance, n=2,100
Ritonavir, Sensitive, n=2,121
Ritonavir, Partially sensitive, n=2,100
Ritonavir, Resistance, n=2,100
Saquinavir, Sensitive, n=2,121
Saquinavir, Partially sensitive, n=2,100
Saquinavir, Resistance, n=2,100
Tipranavir, Sensitive, n=2,121
Tipranavir, Partially sensitive, n=2,100
Tipranavir, Resistance, n=2,100

Adverse events

Collected over Serious adverse events (SAEs) and non-SAEs were collected up to Week 52 for Randomized Phase and from Week 52 to Week 252 for OLE Phase.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG 50 mg- Randomized Phase0/69 (0%)5/69 (7.2%)38/69 (55.1%)
EFV 600 mg- Randomized Phase0/44 (0%)5/44 (11.4%)33/44 (75%)
DTG 50 mg- OLE Phase1/47 (2.1%)5/47 (10.6%)36/47 (76.6%)
EFV 600 mg- OLE Phase0/19 (0%)2/19 (10.5%)16/19 (84.2%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventDTG 50 mg- Randomized PhaseEFV 600 mg- Randomized PhaseDTG 50 mg- OLE PhaseEFV 600 mg- OLE Phase
Psoas abscessInfections and infestations0/690/440/471/19
HeadacheNervous system disorders0/690/440/471/19
PneumoniaInfections and infestations0/691/440/470/19
Patella fractureInjury, poisoning and procedural complications0/691/440/470/19
Immune reconstitution inflammatory syndromeImmune system disorders0/691/440/470/19
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/691/440/470/19
Suicidal ideationPsychiatric disorders0/691/440/470/19
Acute kidney injuryRenal and urinary disorders0/691/440/470/19
Lower limb fractureInjury, poisoning and procedural complications0/690/441/470/19
Foetal deathPregnancy, puerperium and perinatal conditions0/690/441/470/19
Most frequent other events
Showing 10 of 60
Most frequent other events
EventDTG 50 mg- Randomized PhaseEFV 600 mg- Randomized PhaseDTG 50 mg- OLE PhaseEFV 600 mg- OLE Phase
Upper respiratory tract infectionInfections and infestations5/698/4412/475/19
DiarrhoeaGastrointestinal disorders3/6910/444/473/19
HeadacheNervous system disorders9/696/445/474/19
Lower respiratory tract infectionInfections and infestations9/693/444/473/19
DizzinessNervous system disorders3/696/440/470/19
GastroenteritisInfections and infestations1/695/443/472/19
FuruncleInfections and infestations0/690/443/472/19
Pain in extremityMusculoskeletal and connective tissue disorders0/690/441/472/19
Musculoskeletal painMusculoskeletal and connective tissue disorders0/690/440/472/19
DysuriaRenal and urinary disorders0/690/440/472/19

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DTG 50 mgEFV 600 mgTotal
Mean34.6 ± 10.2533.1 ± 7.5634.0 ± 9.29
Sex: Female, Male
Sex: Female, Male(Participants)DTG 50 mgEFV 600 mgTotal
Female301646
Male392867
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DTG 50 mgEFV 600 mgTotal
African American/African Heritage472875
American Indian or Alaska Native11415
Asian - South East Asian Heritage022
White - Arabic/North African Heritage101
White - White/Caucasian/European Heritage9918
Mixed Race112
08

Study locations

28 sites
  • GSK Investigational Site
    Ciudad de Buenos Aires, Buenos Aires C1202ABB, Argentina
  • GSK Investigational Site
    Rosario, Santa Fe S2000PBJ, Argentina
  • GSK Investigational Site
    Manaus, Amazonas 69040-000, Brazil
  • GSK Investigational Site
    Salvador, Bahía 40110-010, Brazil
  • GSK Investigational Site
    Rio de Janeiro, 21040-360, Brazil
  • GSK Investigational Site
    São Paulo, 04121-000, Brazil
  • GSK Investigational Site
    Guadalajara, Jalisco 44160, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44280, Mexico
  • GSK Investigational Site
    Guadalajara, Jalisco 44340, Mexico
  • GSK Investigational Site
    Cuernavaca, Morelos 62290, Mexico
  • GSK Investigational Site
    DF, 14000, Mexico
  • GSK Investigational Site
    San Miguel, Lima Lima 32, Peru
  • GSK Investigational Site
    Iquitos, Loreto Iqui 01, Peru
  • GSK Investigational Site
    Lima, Lima 14, Peru
  • GSK Investigational Site
    Lima, Lima 1, Peru
  • GSK Investigational Site
    Orel, 302040, Russian Federation
  • GSK Investigational Site
    Saint Petersburg, 194214, Russian Federation
  • GSK Investigational Site
    Soweto, Gauteng 2013, South Africa
  • GSK Investigational Site
    Durban, KwaZulu- Natal 4001, South Africa
  • GSK Investigational Site
    Bloemfontein, 9301, South Africa
  • GSK Investigational Site
    Cape Town, 7505, South Africa
  • GSK Investigational Site
    Cape Town, 7700, South Africa
  • GSK Investigational Site
    Klerksdorp, 2574, South Africa
  • GSK Investigational Site
    Observatory, Cape Town, 7925, South Africa
  • GSK Investigational Site
    Westdene, 2092, South Africa
  • GSK Investigational Site
    Bangkok, 10330, Thailand
  • GSK Investigational Site
    Bangkok, 10400, Thailand
  • GSK Investigational Site
    Khon Kaen, 40002, Thailand
09

References and documents

Publications

  • Dooley KE, Kaplan R, Mwelase N, Grinsztejn B, Ticona E, Lacerda M, Sued O, Belonosova E, Ait-Khaled M, Angelis K, Brown D, Singh R, Talarico CL, Tenorio AR, Keegan MR, Aboud M; International Study of Patients with HIV on Rifampicin ING study group. Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial. Clin Infect Dis. 2020 Feb 3;70(4):549-556. doi: 10.1093/cid/ciz256. PubMed 30918967 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Nov 2017, 33 months.

Results were first posted in Feb 2019, 1 year 3 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Infections, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 33. This study's 33 months is above that.

Counting every sponsor, half of 75 studies reached it within 30 months; a quarter within 17 and three quarters within 53.

Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2014
First posted
Jul 1, 2014
StartActual
Jan 23, 2015
Primary completionActual
Nov 2, 2017
CompletionActual
Mar 6, 2020
Results first posted
Feb 21, 2019
Last update
Jan 12, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02178592
Lead sponsor
ViiV Healthcare
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 1, 2014
Start date
Jan 23, 2015
Primary completion
Nov 2, 2017
Completion
Mar 6, 2020
Results posted
Feb 21, 2019
Last update
Jan 12, 2021

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dolutegravir

Start the discussion